Sequel Med Tech announced today that its partner, DEKA R&D, won FDA 510(k) clearance for its automated insulin delivery (AID) system. The twist system, powered by Tidepool, directly measures the volume and flow of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel will market […]
Drug-Device Combinations
The biggest diabetes tech news out of ATTD 2024
Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In the 17th installment at the start of this month, some of the biggest names shared new studies and technologies set to advance the diabetes space. Dexcom, Abbott, Medtronic and more contributed on their end, while […]
Boston Scientific has positive Agent DCB study results
Boston Scientific [WtwhTicker symbol=”BSX”](NYSE: BSX)[/WtwhTicker] reported positive investigational device exemption (IDE) trial data for its Agent drug-coated balloon (DCB). The DCB just this month won FDA approval for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR occurs when plaque or scar tissue obstructs or narrows a stented vessel. Agent serves as […]
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built upon three-year data from more than 100,000 real-world users who outperformed international time in […]
Innovation Zed, Enhance-D collab on insulin dosing management
Innovation Zed announced this week that it entered into a strategic partnership with Enhance-D to optimize diabetes therapy. Switzerland-based Enhance-D develops a digital health platform for enhancing diabetes and exercise management. It designed its platform to empower people with diabetes through cutting-edge technologies and personalized solutions. Ireland-based Innovation Zed develops insulin dosing technology, including the […]
Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy
Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy. Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 automated insulin delivery (AID) system. The company presented results at the Advanced Technologies […]
Roche unveils new CGM tech with predictive AI, outlines diabetes strategy
Roche today gave a presentation debuting its first continuous glucose monitor (CGM) offering that utilizes predictive AI. The company unveiled its Accu-Chek SmartGuide in an event at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy. It remains an investigational device not yet authorized for sale. Julien Boisdron, Roche Diabetes Care’s chief medical […]
Smiths Medical recall affects nearly 86,000 syringe pumps with software issues
Smiths Medical issued a recall for its Medfusion Model 3500 syringe pump due to issues associated with earlier software versions. The ICU Medical unit issued the recall as a correction — not a product removal. It affects 85,961 pumps distributed between Aug. 9, 2022, and Aug. 15, 2023. Smiths Medical initiated the infusion syringe pump […]
Real-world data backs Abbott FreeStyle Libre CGM in tandem with GLP-1s
Abbott (NYSE:ABT) today announced data from two real-world studies highlighting the success of its CGM when used with GLP-1 drugs. Data showed that people with type 2 diabetes using GLP-1s with FreeStyle Libre had a greater improvement in HbA1c compared to GLP-1s alone. Abbott presented the findings at the Advanced Technologies & Treatments for Diabetes […]
Tandem Diabetes Care prices $275M offering
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it priced an offering of convertible senior notes worth $275 million. The San Diego-based automated insulin delivery technology developer plans to sell the notes, due 2029, to qualified institutional buyers. It upsized the offering from the previously announced $250 million aggregate principal amount. The company also offered initial […]